2.1400 0.00 (0.00%)
After hours: 4:59PM EDT
|Bid||2.1300 x 301500|
|Ask||2.1400 x 27000|
|Day's Range||2.1300 - 2.2000|
|52 Week Range||1.7300 - 6.4000|
|Beta (3Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
The largest Insider Buys this week were for Thor Industries Inc. (THO), Sinclair Broadcast Group Inc. (SBGI), OPKO Health Inc. (OPK), and Perspecta Inc. (PRSP). Continue reading...
Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.
OPKO Health (OPK) announced that its subsidiary, BioReference Laboratories, one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City, as its preferred provider of diagnostic testing and to assist with data analytics for its patients. This new collaboration is designed to streamline patient care and offer communication efficiencies between BioReference and the SOMOS network. SOMOS is New York City’s largest multi-cultural physician-led network that serves predominately underserved patient populations.
BioReference Laboratories, Inc., an OPKO Health (OPK) company and one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City, as its preferred provider of diagnostic testing and to assist with data analytics for its patients. This new collaboration is designed to streamline patient care and offer communication efficiencies between BioReference and the SOMOS network.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination (LCD) for the 4Kscore® test, with defined coverage criteria. Under the LCD, Medicare will reimburse the test for patients who meet the defined criteria. The full text of the updated LCD can be found here.
OPKO Health, Inc. (OPK) announces that the Company has submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance for the 4Kscore® test. The 4Kscore® test is a blood test used by health care professionals to assess a patient’s risk of having aggressive prostate cancer after an abnormal prostate specific antigen (PSA) test result, and before a decision is made to perform a biopsy. The de novo pathway for approval is available to medical devices of low-to-moderate risk that do not have an approved predicate device. Per FDA guidelines, the Company expects to receive a response to this request within approximately 180 days.
He was among a group of individuals and companies, including billionaire Phillip Frost, who allegedly participated in a penny stock "pump and dump" scheme.
OPKO Health Inc NASDAQ/NGS:OPKView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for OPK with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding OPK are favorable, with net inflows of $2.95 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
A PSA blood test is standard of care for prostate cancer screening, a critical first step in the identification and diagnosis of prostate cancer, with most national guidelines recommending testing for men between the ages of 45 and 75. Men in higher risk categories, including African Americans and those with a family history of the disease, should consult with their physicians about screening recommendations.
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding ...
BioReference Laboratories, Inc., an OPKO Health company, along with its specialty women’s health division, GenPath, today announces the launch of new testing for aerobic vaginitis (AV). AV is a vaginal infection caused by the overgrowth of aerobic bacteria that triggers an inflammatory response.
Opko Health Inc. (NASDAQ: OPKO) shares are down 35 percent year-to-date, and the company’s first-quarter earnings report suggests management still hasn’t found a way to stop the company’s revenue declines. It can sometimes be difficult to determine if a large option trade represents a trader’s true sentiment toward the underlying stock, but there are clues to watch for.
Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. MGM Resorts International (NYSE: MGM) saw a director last week acquire 80,000 shares of this Las Vegas-based hospitality and entertainment company. At share prices ranging from $25.07 to $25.69, the transaction totaled more than $20.32 million.